Imagene AI
Imagene AI builds AI foundation models and an OI Suite SaaS platform for precision oncology, serving biopharma companies, academic cancer centers, and hospitals with biomarker discovery, NSCLC testing, and clinical trial optimization.
- Company typePrivate
- Founded2021
- HeadquartersTel Aviv, Israel
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Imagene AI does
Imagene AI is an Israel-founded precision oncology company that builds AI-driven biomarker discovery and molecular profiling products for biopharma companies, academic cancer centers, and hospital systems. Its core technology is the Cross-Modality Intelligence Engine, which combines the proprietary CanvOI pan-cancer foundation model, large language models, and biology-tuned analysis engines to learn from histopathology images, molecular profiles, and clinical records simultaneously. The company sells its products through three primary vehicles: the OI Suite, an enterprise SaaS platform offered as cloud, hybrid, or on-premises subscription for biomarker discovery, patient identification, and trial design optimization; LungOI, an AI-powered laboratory-developed test performed in a CLIA-certified and CAP-accredited lab in Phoenix, Arizona, that delivers next-day NSCLC biomarker profiling from biopsy images with Medicare/Medicaid reimbursement; and the OI Suite Discovery Program, a freemium no-code tier for biopharma and academic researchers that functions as a lead-generation funnel for enterprise subscriptions. Additional revenue derives from strategic pharma collaborations, including co-development agreements with Daiichi Sankyo for ADC biomarker discovery and Tempus for AI-enabled NSCLC diagnostics integration.
The company operates from three locations: Tel Aviv (R&D and engineering), Phoenix (CLIA-certified clinical laboratory), and Miami (US headquarters). Its technology stack is anchored on Oracle Cloud Infrastructure, into which CanvOI is deployed, and the platform integrates with Sectra digital pathology workflows, Lumea-operated laboratory information systems, and the Tempus diagnostic pipeline. Imagene's data advantage rests on a proprietary real-world data lake integrating more than 3.5 million tissue samples alongside omics and clinical outcomes, with the foundation model trained on over 1.5 million digitized biopsy images spanning 40+ organs and tissue types. Through 2024-2026, Imagene has expanded its commercial footprint through the Tempus integration, OI Suite Discovery Program launch, Daiichi Sankyo and Shaare Zedek Medical Center data collaborations, and a $23 million Series B led by Larry Ellison, bringing total funding raised to approximately $45 million.
Imagene AI firmographics
Firmographics- Name
- Imagene AI
- Legal name
- Imagene AI Ltd.
- Website
- https://imagene-ai.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Imagene AI builds AI foundation models and an OI Suite SaaS platform for precision oncology, serving biopharma companies, academic cancer centers, and hospitals with biomarker discovery, NSCLC testing, and clinical trial optimization.
- Ownership category
- akta.pro rank
Imagene AI industry classification
Industry- Product category
- Precision Oncology AI Software
- NAICS
- Medical and Diagnostic Laboratories (62151), Software Publishers (5132), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Imagene AI is headquartered
LocationHeadquarters
- HQ city
- Tel Aviv
- HQ country
- Israel
- HQ region
- Middle East
Offices3 records
Markets served
Imagene AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- OI Suite SaaS Subscriptions: Enterprise SaaS platform subscription model for biopharma companies and research institutions. Offers cloud, hybrid, or on-premises deployment options with subscription billing.
- LungOI Laboratory Testing Services: Laboratory Developed Test (LDT) providing rapid NSCLC biomarker profiling. Billable through Medicare & Medicaid Services (CMS) with specific test codes. Revenue from clinical laboratory testing services.
- OI Suite Discovery Program (Freemium): Free access program for researchers in biopharma and academic centers to accelerate biomarker discovery. Serves as lead generation for converting researchers to paid OI Suite enterprise subscriptions.
- Pharma Partnership Agreements: Strategic collaborations with pharmaceutical companies (Daiichi Sankyo, Tempus) for multimodal biomarker discovery, response prediction, and clinical development support.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | OI Suite Discovery - Free access for researchers |
| Subscription | Annual | OI Suite Full Package - Enterprise subscription |
| Subscription | Pay-as-you-go | LungOI Test - Laboratory testing service |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Imagene AI product offering
Product offeringCore offering
Imagene AI develops and sells an Oncology Intelligence (OI) Suite SaaS platform powered by its proprietary CanvOI pan-cancer foundation model and Cross-Modality Intelligence Engine. The platform integrates histopathology, gene expression, mutational profiles, and clinical records to enable biomarker discovery, patient stratification, and clinical trial design for biopharma companies and research institutions. The company also operates a CLIA-certified CAP-accredited laboratory in Phoenix, AZ that delivers its LungOI AI-powered NSCLC biomarker profiling test with next-day results.
Product overview
Imagene AI offers a unified Oncology Intelligence platform centered on OI Suite, which integrates with its flagship products: LungOI (an FDA-cleared AI-powered NSCLC biomarker profiling test) and CanvOI (a pan-cancer foundation model trained on over 1.5 million tissue samples). The Cross-Modality Intelligence Engine powers both OI Suite Discovery (free no-code tier) and full OI Suite enterprise platform. Composite Continuous Scoring provides quantitative IHC assessment. The architecture combines multimodal foundation models with clinical data to support biomarker discovery, patient stratification, and clinical trial optimization.
Differentiator
Problem solved
Functional benefit
Brands
- OI Suite: A SaaS enterprise platform for biomarker discovery, response prediction, patient stratification, and evidence-based trial design in oncology.
- LungOI
- CanvOI
Products and services
- OI Suite Enterprise SaaS platform for biomarker discovery, indication expansion, and patient identification across multiple therapeutic areas, powered by the Cross-Modality Intelligence Engine and CanvOI foundation model. Offered to biopharma companies and research institutions.
- OI Suite Discovery Program Free no-code access tier of OI Suite for biopharma and academic researchers, enabling rapid biomarker hypothesis exploration and predictive model development using the CanvOI foundation model.
- LungOI AI-powered multi-gene NSCLC biomarker profiling laboratory developed test that rapidly identifies actionable alterations directly from biopsy images or glass slides, delivering next-day results to hospitals, oncologists, and pathologists through a CLIA-certified CAP-accredited laboratory.
Quantifiable outcome
- Next-day test results vs weeks for traditional molecular testing
- +4 more outcomes
Companies that use Imagene AI
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles3 records
Imagene AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability9 records
Feature6 records
Imagene AI partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- Daiichi SankyocoreCollaboration leveraging Imagene's OI Suite powered by CanvOI and large-scale multimodal real-world data lake to advance biomarker discovery and response prediction in oncology drug development. Daiichi Sankyo will use the platform to generate insights from H&E and IHC whole-slide images in the context of molecular profiles and clinical outcomes for ADC development programs.
- Shaare Zedek Medical CentercoreStrategic data-AI collaboration combining Shaare Zedek's real-world data and clinical expertise with Imagene AI's OI Suite to advance biomarker discovery and accelerate precision cancer care. Shaare Zedek provides de-identified multimodal longitudinal data to enrich Imagene's real-world data lake.
- Sheba Medical CentercorePrecision Oncology Intelligence Alliance to scale personalized cancer care. Collaboration leveraging Imagene's AI technology and Sheba's clinical expertise for advanced oncology research and patient care.
- TempuscoreCollaboration to advance AI-driven diagnostics for non-small cell lung cancer. Tempus integrates Imagene's AI-based biomarker detection into its diagnostic offerings to provide clinicians more actionable data for treatment decisions.
- OraclecoreOracle Cloud Infrastructure powers CanvOI foundation model and OI Suite platform. Oracle's highly performant and secure cloud infrastructure helps Imagene improve access to care, drive informed decisions, and lower costs. Larry Ellison, Oracle Chairman & CTO, is a key investor.
- Ellison Medical InstitutecoreCo-development partner for CanvOI foundation model. David Agus, Founding CEO of Ellison Medical Institute, is a key advisor and board member. Research collaboration on oncology intelligence.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Imagene AI competitors and assessment
Company assessmentBroad incumbents
- Tempus AI: Tempus is a large AI-driven precision medicine platform combining multi-modal data, molecular profiling, and a CLIA lab for oncology. Imagene's LungOI test is distributed through Tempus, but Tempus also competes with Imagene's OI Suite in biomarker discovery for biopharma.
- Foundation Medicine (Roche): Foundation Medicine is the dominant comprehensive genomic profiling provider in oncology, owned by Roche. Its CGP assays compete directly with LungOI for NSCLC molecular profiling and broader biomarker-driven treatment selection.
- Guardant Health: Guardant Health provides liquid-biopsy and tissue-based molecular profiling in oncology with broad payer coverage. Its Guardant360 CDx competes with LungOI for NSCLC biomarker profiling, particularly where turnaround time is critical.
- Verily (Alphabet): Verily, an Alphabet precision health company, invests in multimodal AI for clinical research and biomarker discovery with deep-pocketed infrastructure. It is a broader incumbent in the same multi-modal, foundation-model-enabled precision oncology space Imagene targets for biopharma.
Direct peers
- Paige AI: Paige builds AI foundation models and clinical applications for digital pathology and cancer diagnostics. It is the closest direct competitor to Imagene's CanvOI and OI Suite in computational histopathology, with a focus on FDA-cleared clinical deployments.
- PathAI: PathAI develops AI-powered pathology tools for biomarker discovery and clinical diagnostics, partnering with biopharma and academic centers. It directly overlaps with Imagene's biomarker discovery and digital pathology foundation model approach.
- Artera AI: Artera AI builds multimodal AI models that integrate pathology and clinical data to predict treatment outcomes in prostate and other cancers. It is a direct comparable to Imagene in combining histopathology foundation models with clinical decision support for biopharma and providers.
- Owkin: Owkin applies AI to multimodal patient data for biomarker discovery, drug development, and diagnostics, working closely with biopharma and academic centers. It overlaps with Imagene's OI Suite positioning in pharma-facing multimodal biomarker discovery.
- Lunit: Lunit develops AI-powered medical image analysis and biomarker prediction products, including pathology and mammography solutions with biopharma partnerships. It competes with Imagene in AI-driven biomarker profiling and predictive analytics for oncology.
Emerging players
- Proscia: Proscia builds AI-enabled digital pathology software for life sciences and diagnostic labs, integrating foundation models into pathology workflows. It overlaps with Imagene's OI Suite and digital pathology integrations (e.g., Sectra) at the workflow and biomarker discovery layer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Imagene AI social profiles
Digital presenceImagene AI compliance and trust
Trust signalCompliance3 records
Imagene AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Imagene AI leadership team
Management profileNumber of profiles
Profiles17 records
Imagene AI funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Imagene AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Imagene AI
What does Imagene AI do?
Imagene AI develops and sells an Oncology Intelligence (OI) Suite SaaS platform powered by its proprietary CanvOI pan-cancer foundation model and Cross-Modality Intelligence Engine. The platform integrates histopathology, gene expression, mutational profiles, and clinical records to enable biomarker discovery, patient stratification, and clinical trial design for biopharma companies and research institutions. The company also operates a CLIA-certified CAP-accredited laboratory in Phoenix, AZ that delivers its LungOI AI-powered NSCLC biomarker profiling test with next-day results.
Is Imagene AI a public or private company?
Imagene AI is a private company. It is classified as venture growth investor backed and is currently operating.
When was Imagene AI founded?
Imagene AI was founded in 2021. It employs 11 to 50 people.
Where is Imagene AI based?
Imagene AI is headquartered in Tel Aviv, Israel, in the Middle East region.
How does Imagene AI make money?
Four revenue lines are on record. OI Suite SaaS Subscriptions are the primary driver. The others are lungOI Laboratory Testing Services, OI Suite Discovery Program (Freemium) and pharma Partnership Agreements.
Who are Imagene AI's main competitors?
Broad incumbents on record are Tempus AI, Foundation Medicine (Roche), Guardant Health and Verily (Alphabet). Direct peers are Paige AI, PathAI, Artera AI, Owkin and Lunit. Proscia is listed as an emerging player.
Does Imagene AI have an API?
No public API is recorded for Imagene AI.
What industry is Imagene AI in?
Imagene AI's product category is Precision Oncology AI Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 62151 and its SIC code is 8071.